What is N0728 used for?

N0728 is indicated for Type 2 diabetes.

N0728 is developed by Eurofarma Laboratorios S.A..

What are the side effects of N0728?

Common side effects include Increased risk of diabetic ketoacidosis.

Last reviewed 2026-04-23 · How we verify

N0728

Eurofarma Laboratorios S.A. · Phase 3 active Small molecule

N0728 is a small molecule that targets the SGLT2 receptor.

N0728 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Generic name	N0728
Sponsor	Eurofarma Laboratorios S.A.
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 3

Mechanism of action

By inhibiting SGLT2, N0728 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful for the treatment of type 2 diabetes.

Approved indications

Type 2 diabetes

Common side effects

Increased risk of diabetic ketoacidosis

Key clinical trials

Efficacy and Safety of Two Fixed-dose Combinations in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. (BENIPRO) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

N0728 CI brief — competitive landscape report
N0728 updates RSS · CI watch RSS
Eurofarma Laboratorios S.A. portfolio CI